Abstract:Ruyu Han, 1, &ast Leijuan Gan, 1, &ast Liyu Sun, 1 Mengran Lang, 2 Xindi Tian, 1 Kangwei Zhu, 1 Lu Chen, 1 Guangtao Li, 1 Tianqiang Song 1 1 Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin, 300060, People's Republic of China; 2 Hepatobiliary Surgery Department, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Tianqiang Song, Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin, 300060, People's Republic of China, Tel +86-22-23340123, Fax +86-22-23537796, Email Purpose: This study aimed to investigate the benefit of conversion therapy for patients with unresectable hepatocellular carcinoma (HCC). Patients and Methods: A retrospective cohort study was conducted involving 40 patients initially deemed unresectable HCC (uHCC). They received surgery following successful conversion therapy involving lenvatinib. The patients were matched in a 1:1 ratio to with a control group who underwent direct surgery, based on pre-treatment clinical data. Results: The median recurrence-free survival (RFS) duration for the conversion therapy cohort was notably longer than that of the direct surgery cohort (25 months vs 11 months). Furthermore, the 1- and 2-year RFS rates were significantly higher in the conversion therapy group compared to the direct surgery group (1 year: 70.5% vs 40.1%; 2 years: 49.0% vs 19.1%). The survival curves indicated a statistically significantly longer RFS in the conversion therapy cohort compared to the direct surgery cohort (P = 0.007). While patients achieving good remission based on both RECIST 1.1 and mRECIST criteria showed superior median RFS, no significant disparity was observed in the survival curves. The subgroup analysis revealed significantly improved prognosis among patients in the conversion therapy group who were male, older, had a history of alcohol consumption, were non-smokers, had liver cirrhosis, possessed Child-Pugh A liver function, had a tumor diameter exceeding 5 cm, and had an AFP ≥ 400 ng/mL. Among the cohort of 40 patients, only 8 individuals encountered severe adverse reactions, which were managed through dose reduction. None of the patients experienced multiple severe adverse reactions concurrently. Conclusion: For patients with unresectable hepatocellular carcinoma, conversion therapy offers a significantly better prognosis than direct surgery for uHCC patients. Keywords: hepatocellular carcinoma, conversion therapy, recurrence-free survival, hepatic resection Hepatocellular carcinoma (HCC) presents a formidable challenge to public health, characterized by high incidence and mortality rates compared to other malignancies. 1 The primary radical interventions for HCC encompass hepatic resection (HR), liver transplantation (LT), and radiofrequency ablation (RFA). 2 These modalities exclusively recommended for patients in the early stages. 3 Unfortunately, the majority of HCC cases are diagnosed at intermediate to advanced stages, precluding the feasibility of surgical interventions. 4,5 Historically, therapeutic options for these patients were constrained due to the absence of effective pharmaceutical interventions. 6 However, the advent of targeted therapies and immunotherapies has substantially broadened the therapeutic armamentarium for HCC, yielding increasingly efficacious treatments. 7–9 Consequently, the landscape of therapeutic options for patients with intermediate and advanced HCC has progressively expanded. In recent years, conversion therapy has emerged as a key component in the diagnostic and therapeutic strategy for intermediate and advanced HCC. 10,11 Conversion therapy aims to offer localized or systemic treatment to patients initially deemed unresectable, potentially enabling them to undergo radical treatment. 5 Such patients can be categorized into two distinct groups. One category comprises those who are unresectable due to -Abstract Truncated-

Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma

ASO Visual Abstract: Hepatectomy Following Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy in Patients with Unresectable Hepatocellular Carcinoma

Hepatectomy After Conversion Therapy with Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitors and Anti-PD-1 Antibodies for Initially Unresectable Hepatocellular Carcinoma

Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations

Initially Unresectable Hepatocellular Carcinoma Treated by Combination Therapy of Tyrosine Kinase Inhibitor and Anti-Pd-1 Antibody Followed by Resection.

Surgery after Conversion Therapy with PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients

Conversion of Initially Unresectable Hepatocellular Carcinoma (HCC) with Triple-Combination Therapy (lenvatinib, Anti-Pd-1 Antibodies, and Transarterial Therapy): A Retrospective Analysis

Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma

Safety and Survival Outcomes of Liver Resection following Triple Combination Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma

A real-world study of PD-1 inhibitors combined with TKIs for HCC with major vascular invasion as the conversion therapy: A prospective, non-randomized, open-label cohort study

Systemic Chemotherapy Improves Outcome of Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors

Evaluating Tislelizumab, Lenvatinib, and FOLFOX4-HAIC as a Conversion Therapy for Unresectable Hepatocellular Carcinoma

Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study

Reassessment of Palliative Surgery in Conversion Therapy of Previously Unresectable Hepatocellular Carcinoma: Two Case Reports and Review of Literature

Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study

Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study

A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma

Transarterial chemoembolization combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma: A prospective, single-arm, multicenter study.

Resection of unresectable hepatocellular carcinoma after conversion therapy with apatinib and camrelizumab: a case report and literature review

Benefit of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score-Matched Study